newsfilter
← Latest News
PR Newswire·

BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808

BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the U.S. Food and Drug Administration (FDA) has approved the...